# Serplulimab+Regorafenib +Hepatic Artery Bicarbonate Infusion in Patients With Colorectal Cancer and Liver Metastases

> **NCT05894837** · PHASE2 · UNKNOWN · sponsor: **Second Affiliated Hospital, School of Medicine, Zhejiang University** · enrollment: 30 (estimated)

## Conditions studied

- Colorectal Cancer
- Liver Metastases

## Interventions

- **DRUG:** Serplulimab+Regorafenib
- **DRUG:** Hepatic Artery Bicarbonate Infusion

## Key facts

- **NCT ID:** NCT05894837
- **Lead sponsor:** Second Affiliated Hospital, School of Medicine, Zhejiang University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2023-06-01
- **Primary completion:** 2024-06-01
- **Final completion:** 2025-06-01
- **Target enrollment:** 30 (ESTIMATED)
- **Last updated:** 2023-06-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05894837

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05894837, "Serplulimab+Regorafenib +Hepatic Artery Bicarbonate Infusion in Patients With Colorectal Cancer and Liver Metastases". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT05894837. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*